FGFR4 and hepatocellular carcinoma: FGFR4-selective inhibitors have been tested in clinical trials of patients with hepatocellular carcinoma (HCC), but the patient response to FGFR4-selective inhibitors in HCC appeared to be unsatisfactory [51].